{"id":"W2553523735","doi":"10.1182/blood.v112.11.764.764","title":"Phase 1/2 Trial of the XIAP Antisense Oligonucleotide (AEG35156) in Combination with Idarubicin and Cytarabine in Patients with Relapsed/Refractory AML","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Cell death mechanisms and regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"Aegera Therapeutics (Canada); Hôpital Maisonneuve-Rosemont; Princess Margaret Cancer Centre","funders":"","keywords":"Cytarabine; Medicine; Internal medicine; Idarubicin; Gastroenterology; Regimen; Neutropenia; Refractory (planetary science); XIAP; Febrile neutropenia; Adverse effect; Nausea; Phases of clinical research; Chemotherapy regimen; Chemotherapy; Surgery; Pharmacology; Apoptosis; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001104841,0.001379887,0.001965367,0.0004460349,0.0003846918,0.0006515516,0.0006534453,0.0007935453,0.002069837],"category_scores_gemma":[0.0006086525,0.0004677079,0.000874639,0.0002906229,0.0006492745,0.0004862635,0.0002776948,0.00259872,0.0004581174],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006094763,"about_ca_system_score_gemma":0.001013097,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007871801,"about_ca_topic_score_gemma":0.001579884,"domain_scores_codex":[0.99972,0.0001387016,0.00001550989,0.00005222502,0.00001863885,0.00005496601],"domain_scores_gemma":[0.9996365,0.00006357324,0.00006068781,0.00004060237,0.00002072327,0.0001779351],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6252521,0.1015883,0.00833589,0.0006728551,0.001051183,0.0007748327,0.0006061263,0.005400722,0.1255416,0.0006166386,0.004321575,0.1258381],"study_design_scores_gemma":[0.456562,0.519694,0.009696072,0.00003703509,0.0002923835,0.000378408,0.00006071702,0.001791003,0.008586133,0.0001921829,0.002678211,0.00003183437],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9955427,0.0008701692,0.0003475521,0.0002534402,0.00009217859,0.001610427,0.0003034946,0.00005537774,0.0009245852],"genre_scores_gemma":[0.9929568,0.0008183763,0.001395403,0.0004878508,0.0001545739,0.001654919,0.0008760521,0.00001899194,0.001636929],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002069837,"threshold_uncertainty_score":0.006924272,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.00509312970122007,"score_gpt":0.1997481760663979,"score_spread":0.1946550463651778,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}